Publications by authors named "Chester Lin"

Claim this Profile
R
Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160-mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers.
Bilal Tariq, Chester Lin, Vaibhav Mundra, Yang Gao, Dan Zhang

Clin Pharmacol Drug Dev· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Bilal Tariq, Ying C Ou, Jennifer C Stern, Vaibhav Mundra, Nicole Wong Doo, Chester Lin

Leuk Lymphoma· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
Song Mu, Chester Lin, Anna Skrzypczyk-Ostaszewicz, Iurie Bulat, Marina Maglakelidze

Cancer Chemother Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.
Anthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, Jordan Berlin, Thomas Witzig, Chester Lin

Oncologist· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis